Methylene Blue dosage

Protocol

1. 1

   Measure the dose

   Typical Methylene Blue dose is 70 mg (Oral cognitive use 0.5 to 4 mg/kg; IV methemoglobinemia dose 1 to 2 mg/kg). Use a weight-based calculator for individual adjustments.

   Open tool →
2. 2

   Set the frequency

   Administer 1 to 3 times daily for cognitive use; single IV dose for methemoglobinemia. Half-life of 5.5 hours anchors the dosing interval.

   Open tool →
3. 3

   Cycle if needed

   No formal cycling protocol; cognitive use protocols run weeks to months continuously

   Open tool →
4. 4

   Monitor for side effects

   Watch for: blue-green urine and sweat; skin and oral mucosa staining; GI upset; headache. Stop or reduce dose if tolerability breaks down.

Why this dose

Mitochondrial electron carrier at low doses (cytochrome c shuttle to complex IV) and methemoglobin reductase substrate at higher doses; potent MAO-A inhibitor across the dose range.

The typical dose (70 mg) reflects Oral cognitive use 0.5 to 4 mg/kg; IV methemoglobinemia dose 1 to 2 mg/kg. Individual response varies with body weight, baseline status, concurrent training, and concurrent medications, so the labeled range is the starting point rather than the prescription.

How to administer

Methylene Blue is administered via the oral or intravenous routes. Oral dosing is straightforward: take with water, with or without food unless specifically noted.

Onset of action runs around 1 hour after administration. Peak effect lands near 1.5 hours post-dose. Plan the administration window so that peak effect lines up with whatever outcome you are dosing for, whether that is training, sleep, or symptom coverage.

Half-life note: Terminal half-life around 5 to 6 hours; oral bioavailability around 70 to 75%

Cycling and tolerance

No formal cycling protocol; cognitive use protocols run weeks to months continuously

Effects to expect at typical dose

• FDA approved for methemoglobinemia and ifosfamide-induced encephalopathy
• Mitochondrial electron-transport support at low doses (0.5 to 4 mg/kg) via cytochrome c shuttle
• Potent MAO-A inhibitor; serotonin syndrome risk with SSRIs, SNRIs, MAOIs, fentanyl, tramadol, St John's wort
• Causes harmless blue-green urine and sweat coloration; useful adherence marker
• G6PD deficiency is an absolute contraindication; can trigger massive hemolysis
• Cognitive-enhancement evidence is preliminary, mostly preclinical and small fMRI trials

Side effects and interactions

Common side effects

• blue-green urine and sweat
• skin and oral mucosa staining
• GI upset
• headache
• dizziness

Notable interactions

• SSRIs and SNRIs (major): serotonin syndrome, potentially fatal
• MAOIs (major): additive MAO inhibition, serotonin syndrome risk
• fentanyl, tramadol, meperidine (major): serotonin syndrome risk
• dextromethorphan (major): serotonin syndrome risk
• St John's wort (major): serotonin syndrome risk

Lists above cover commonly reported and well-characterized items. They are not exhaustive: review the full Methylene Blue profile and discuss with a clinician familiar with your medication list before starting, particularly if you are on prescription therapy or have a chronic condition.

Regulatory snapshot

WADA status

allowed

DEA / Rx

Not scheduled in the US

Pregnancy

Contraindicated

Legal status

Prescription (injectable, FDA approved); supplement form (oral) widely available; not scheduled

Do not use if

• G6PD deficiency
• pregnancy
• concurrent serotonergic medication
• severe renal impairment
• infants under 6 months

Related research